<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39429028</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1525-1489</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>21</Day></PubDate></JournalIssue><Title>Journal of intensive care medicine</Title><ISOAbbreviation>J Intensive Care Med</ISOAbbreviation></Journal><ArticleTitle>Outcomes Associated with the use of High Dose Corticosteroids and IL-6 Inhibitors for the Treatment of Acute Respiratory Distress Syndrome Secondary to SARS COV-2.</ArticleTitle><Pagination><StartPage>8850666241287514</StartPage><MedlinePgn>8850666241287514</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/08850666241287514</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">During the COVID-19 pandemic, treatment strategies evolved rapidly. The RECOVERY trial established corticosteroids as the standard care for reducing mortality in COVID-19 patients. However, some critical care clinicians began using doses higher than those recommended in RECOVERY.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To characterize the use of high-dose corticosteroids and IL-6 inhibitors in critically ill COVID-19 patients and examine their association with adverse drug events (ADEs).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A retrospective cohort study of 320 electronic health records (January 1, 2020 - June 30, 2022) was conducted on COVID-19 patients requiring high-flow oxygen or mechanical ventilation. Patients were categorized based on corticosteroid dose: "high dose dexamethasone" (daily dose greater than 12 mg and/or for longer than 10 days), "low dose dexamethasone" (daily dose 12 mg or less for 10 days or less), and "no dexamethasone" (no corticosteroid therapy). Subgroups were created based on IL-6 inhibitor use.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">High-dose dexamethasone was associated with increased odds of ADEs compared to low dose (OR 2.55, 95% CI 1.45 to 4.49) and no dexamethasone (OR 6.29, 95% CI 2.08 to 19.03). No additional efficacy benefit was observed in patients receiving high dose corticosteroids when compared to low dose corticosteroids. Patients receiving both an IL-6 inhibitor and high-dose dexamethasone had further increased odds of ADEs. High-dose dexamethasone was also associated with increased mortality compared to low dose (OR 3.78, 95% CI 1.97-7.25) and no dexamethasone (OR 15.22, 95% CI 3.27-70.74).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Acknowledging the risk for residual confounding, higher doses of dexamethasone were associated with increased ADEs and mortality. These findings highlight the need for careful consideration of the use of high-dose dexamethasone.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Milic</LastName><ForeName>Tessa</ForeName><Initials>T</Initials><Identifier Source="ORCID">0009-0000-6321-1807</Identifier><AffiliationInfo><Affiliation>Lower Mainland Pharmacy Services, Fraser Health Authority, Royal Columbian Hospital, New Westminster, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Kieran</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Lower Mainland Pharmacy Services, Fraser Health Authority, Surrey Memorial Hospital, Surrey, British Columbia, Canada.</Affiliation><Identifier Source="RINGGOLD">91444</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mitra</LastName><ForeName>Anish</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Lower Mainland Pharmacy Services, Fraser Health Authority, Surrey Memorial Hospital, Surrey, British Columbia, Canada.</Affiliation><Identifier Source="RINGGOLD">91444</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stabler</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Lower Mainland Pharmacy Services, Fraser Health Authority, Surrey Memorial Hospital, Surrey, British Columbia, Canada.</Affiliation><Identifier Source="RINGGOLD">91444</Identifier></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Intensive Care Med</MedlineTA><NlmUniqueID>8610344</NlmUniqueID><ISSNLinking>0885-0666</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">IL-6 inhibitor</Keyword><Keyword MajorTopicYN="N">acute respiratory distress syndrome</Keyword><Keyword MajorTopicYN="N">dexamethasone</Keyword><Keyword MajorTopicYN="N">tocilizumab</Keyword></KeywordList><CoiStatement>Declaration of Conflicting InterestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>21</Day><Hour>10</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>21</Day><Hour>10</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>21</Day><Hour>4</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39429028</ArticleId><ArticleId IdType="doi">10.1177/08850666241287514</ArticleId></ArticleIdList></PubmedData></PubmedArticle>